The clinical landscape of HDAC inhibitors

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

There are eleven human isoforms of the zinc-dependent histone deacetylases (HDACs). These proteins are involved in the removal of acetyl and fatty acid acyl chains from polyamines and lysine residues in proteins. Of particular importance is histone deacetylation, the inhibition of which leads to transcriptional activation. Over the last two decades, many small molecule HDAC inhibitors have reached clinical development, with five approved drugs to date in oncology. This chapter reviews the recent progress in HDAC inhibitor therapy and discusses how isoform selectivity is central to exploiting the therapeutic potential of these compounds in cancer as well as other indications.
Original languageEnglish
Title of host publicationMedical Epigenetics
PublisherElsevier
Chapter38
Pages885-899
Number of pages15
ISBN (Print)9780128239285
DOIs
Publication statusPublished - 3 Sep 2021

Cite this